The Bright Elusive Butterfly of Value in Health Technology Development; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies”
The current system of health technology development is characterised by multiple misalignments. The “supply” side (innovation policy-makers, entrepreneurs, investors) and the “demand” side (health policy-makers, regulators, health technology assessment, purchasers) operate under different – and conf...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kerman University of Medical Sciences
2018-01-01
|
| Series: | International Journal of Health Policy and Management |
| Subjects: | |
| Online Access: | http://www.ijhpm.com/article_3372_ccb4fbb81d08d24206fba5ba74219427.pdf |
| _version_ | 1798045953018560512 |
|---|---|
| author | Trisha Greenhalgh Nick Fahy Sara Shaw |
| author_facet | Trisha Greenhalgh Nick Fahy Sara Shaw |
| author_sort | Trisha Greenhalgh |
| collection | DOAJ |
| description | The current system of health technology development is characterised by multiple misalignments. The “supply” side (innovation policy-makers, entrepreneurs, investors) and the “demand” side (health policy-makers, regulators, health technology assessment, purchasers) operate under different – and conflicting – logics. The system is less a “pathway” than an unstable ecosystem of multiple interacting sub-systems. “Value” means different things to each of the numerous actors involved. Supply-side dynamics are built on fictions; regulatory checks and balances are designed to assure quality, safety and efficacy, not to ensure that technologies entering the market are either desirable or cost-effective. Assessment of comparative and cost-effectiveness usually comes too late in the process to shape an innovation’s development.
We offer no simple solutions to these problems, but in the spirit of commencing a much-needed public debate, we suggest some tentative ways forward. First, universities and public research funders should play a more proactive role in shaping the system. Second, the role of industry in forging long-term strategic partnerships for public benefit should be acknowledged (though not uncritically). Third, models of “responsible innovation” and public input to research priority-setting should be explored. Finally, the evidence base on how best to govern inter-sectoral health research partnerships should be developed and applied. |
| first_indexed | 2024-04-11T23:29:39Z |
| format | Article |
| id | doaj.art-0910fc515bf4436dab140edb7fb65a1f |
| institution | Directory Open Access Journal |
| issn | 2322-5939 2322-5939 |
| language | English |
| last_indexed | 2024-04-11T23:29:39Z |
| publishDate | 2018-01-01 |
| publisher | Kerman University of Medical Sciences |
| record_format | Article |
| series | International Journal of Health Policy and Management |
| spelling | doaj.art-0910fc515bf4436dab140edb7fb65a1f2022-12-22T03:57:09ZengKerman University of Medical SciencesInternational Journal of Health Policy and Management2322-59392322-59392018-01-0171818510.15171/IJHPM.2017.65The Bright Elusive Butterfly of Value in Health Technology Development; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies”Trisha Greenhalgh0Nick Fahy1Sara Shaw2Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UKNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UKNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UKThe current system of health technology development is characterised by multiple misalignments. The “supply” side (innovation policy-makers, entrepreneurs, investors) and the “demand” side (health policy-makers, regulators, health technology assessment, purchasers) operate under different – and conflicting – logics. The system is less a “pathway” than an unstable ecosystem of multiple interacting sub-systems. “Value” means different things to each of the numerous actors involved. Supply-side dynamics are built on fictions; regulatory checks and balances are designed to assure quality, safety and efficacy, not to ensure that technologies entering the market are either desirable or cost-effective. Assessment of comparative and cost-effectiveness usually comes too late in the process to shape an innovation’s development. We offer no simple solutions to these problems, but in the spirit of commencing a much-needed public debate, we suggest some tentative ways forward. First, universities and public research funders should play a more proactive role in shaping the system. Second, the role of industry in forging long-term strategic partnerships for public benefit should be acknowledged (though not uncritically). Third, models of “responsible innovation” and public input to research priority-setting should be explored. Finally, the evidence base on how best to govern inter-sectoral health research partnerships should be developed and applied.http://www.ijhpm.com/article_3372_ccb4fbb81d08d24206fba5ba74219427.pdfInnovation PolicyHealth PolicyHealth Technology AssessmentTechnology-Based VenturesHealth Research Systems |
| spellingShingle | Trisha Greenhalgh Nick Fahy Sara Shaw The Bright Elusive Butterfly of Value in Health Technology Development; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies” International Journal of Health Policy and Management Innovation Policy Health Policy Health Technology Assessment Technology-Based Ventures Health Research Systems |
| title | The Bright Elusive Butterfly of Value in Health Technology Development; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies” |
| title_full | The Bright Elusive Butterfly of Value in Health Technology Development; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies” |
| title_fullStr | The Bright Elusive Butterfly of Value in Health Technology Development; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies” |
| title_full_unstemmed | The Bright Elusive Butterfly of Value in Health Technology Development; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies” |
| title_short | The Bright Elusive Butterfly of Value in Health Technology Development; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies” |
| title_sort | bright elusive butterfly of value in health technology development comment on providing value to new health technology the early contribution of entrepreneurs investors and regulatory agencies |
| topic | Innovation Policy Health Policy Health Technology Assessment Technology-Based Ventures Health Research Systems |
| url | http://www.ijhpm.com/article_3372_ccb4fbb81d08d24206fba5ba74219427.pdf |
| work_keys_str_mv | AT trishagreenhalgh thebrightelusivebutterflyofvalueinhealthtechnologydevelopmentcommentonprovidingvaluetonewhealthtechnologytheearlycontributionofentrepreneursinvestorsandregulatoryagencies AT nickfahy thebrightelusivebutterflyofvalueinhealthtechnologydevelopmentcommentonprovidingvaluetonewhealthtechnologytheearlycontributionofentrepreneursinvestorsandregulatoryagencies AT sarashaw thebrightelusivebutterflyofvalueinhealthtechnologydevelopmentcommentonprovidingvaluetonewhealthtechnologytheearlycontributionofentrepreneursinvestorsandregulatoryagencies AT trishagreenhalgh brightelusivebutterflyofvalueinhealthtechnologydevelopmentcommentonprovidingvaluetonewhealthtechnologytheearlycontributionofentrepreneursinvestorsandregulatoryagencies AT nickfahy brightelusivebutterflyofvalueinhealthtechnologydevelopmentcommentonprovidingvaluetonewhealthtechnologytheearlycontributionofentrepreneursinvestorsandregulatoryagencies AT sarashaw brightelusivebutterflyofvalueinhealthtechnologydevelopmentcommentonprovidingvaluetonewhealthtechnologytheearlycontributionofentrepreneursinvestorsandregulatoryagencies |